title: Risk factors for severe anaemia during telaprevir-based triple therapy: is acquired renal dysfunction the missing link?
authors.affiliation: Hepatogastroenterology Unit, Centre Hospitalier, Pau, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Pariente
authors.forename: André-Jean
authors.initials: AJ
authors.lastname: Rémy
authors.forename: Bruno
authors.initials: B
authors.lastname: Lesgourgues
authors.forename: Hervé
authors.initials: H
authors.lastname: Hagège
mesh_terms: D000740:Anemia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D000998:Antiviral Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate; D006454:Hemoglobins / Q000378:metabolism; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D009842:Oligopeptides / Q000009:adverse effects*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D006454:Hemoglobins; D009842:Oligopeptides; C486464:telaprevir